This finding suggests that panduratin A may preferentially target the EGFR T790M mutation, which is a critical focus for therapeutic strategies aimed at overcoming drug resistance in NSCLC, as reported in previous studies [48]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.